# Ixekizumab in the Treatment of Bullous Pemphigoid

> **NCT03099538** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 4 (actual)

## Conditions studied

- Bullous Pemphigoid
- Pemphigoid

## Interventions

- **DRUG:** Ixekizumab

## Key facts

- **NCT ID:** NCT03099538
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-06-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099538, "Ixekizumab in the Treatment of Bullous Pemphigoid". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03099538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*